vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and HEARTLAND EXPRESS INC (HTLD). Click either name above to swap in a different company.

HEARTLAND EXPRESS INC is the larger business by last-quarter revenue ($179.4M vs $154.2M, roughly 1.2× BridgeBio Pharma, Inc.). HEARTLAND EXPRESS INC runs the higher net margin — -10.8% vs -126.2%, a 115.4% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs -26.1%). HEARTLAND EXPRESS INC produced more free cash flow last quarter ($-44.2M vs $-56.5M).

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

Heartland Express is an American trucking company headquartered in North Liberty, Iowa. The company offers truckload shipping services across the United States.

BBIO vs HTLD — Head-to-Head

Bigger by revenue
HTLD
HTLD
1.2× larger
HTLD
$179.4M
$154.2M
BBIO
Growing faster (revenue YoY)
BBIO
BBIO
+2547.2% gap
BBIO
2521.2%
-26.1%
HTLD
Higher net margin
HTLD
HTLD
115.4% more per $
HTLD
-10.8%
-126.2%
BBIO
More free cash flow
HTLD
HTLD
$12.3M more FCF
HTLD
$-44.2M
$-56.5M
BBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BBIO
BBIO
HTLD
HTLD
Revenue
$154.2M
$179.4M
Net Profit
$-194.6M
$-19.4M
Gross Margin
94.7%
Operating Margin
-90.5%
-12.7%
Net Margin
-126.2%
-10.8%
Revenue YoY
2521.2%
-26.1%
Net Profit YoY
27.2%
-949.2%
EPS (diluted)
$-1.00
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
HTLD
HTLD
Q4 25
$154.2M
$179.4M
Q3 25
$120.7M
$196.5M
Q2 25
$110.6M
$210.4M
Q1 25
$116.6M
$219.4M
Q4 24
$242.6M
Q3 24
$259.9M
Q2 24
$274.8M
Q1 24
$211.1M
$270.3M
Net Profit
BBIO
BBIO
HTLD
HTLD
Q4 25
$-194.6M
$-19.4M
Q3 25
$-184.9M
$-8.3M
Q2 25
$-183.8M
$-10.9M
Q1 25
$-169.6M
$-13.9M
Q4 24
$-1.9M
Q3 24
$-9.3M
Q2 24
$-3.5M
Q1 24
$-36.2M
$-15.1M
Gross Margin
BBIO
BBIO
HTLD
HTLD
Q4 25
94.7%
Q3 25
94.6%
Q2 25
96.7%
Q1 25
97.7%
Q4 24
Q3 24
Q2 24
Q1 24
99.7%
Operating Margin
BBIO
BBIO
HTLD
HTLD
Q4 25
-90.5%
-12.7%
Q3 25
-120.3%
-3.7%
Q2 25
-121.4%
-5.9%
Q1 25
-89.5%
-6.8%
Q4 24
0.4%
Q3 24
-2.7%
Q2 24
0.1%
Q1 24
0.2%
-5.3%
Net Margin
BBIO
BBIO
HTLD
HTLD
Q4 25
-126.2%
-10.8%
Q3 25
-153.2%
-4.2%
Q2 25
-166.2%
-5.2%
Q1 25
-145.4%
-6.3%
Q4 24
-0.8%
Q3 24
-3.6%
Q2 24
-1.3%
Q1 24
-17.1%
-5.6%
EPS (diluted)
BBIO
BBIO
HTLD
HTLD
Q4 25
$-1.00
$-0.24
Q3 25
$-0.95
$-0.11
Q2 25
$-0.95
$-0.14
Q1 25
$-0.88
$-0.18
Q4 24
$-0.03
Q3 24
$-0.12
Q2 24
$-0.04
Q1 24
$-0.20
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
HTLD
HTLD
Cash + ST InvestmentsLiquidity on hand
$570.1M
$18.5M
Total DebtLower is stronger
$2.0B
$154.1M
Stockholders' EquityBook value
$-2.1B
$755.3M
Total Assets
$936.0M
$1.2B
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
HTLD
HTLD
Q4 25
$570.1M
$18.5M
Q3 25
$643.0M
$32.7M
Q2 25
$756.9M
$22.9M
Q1 25
$540.6M
$23.9M
Q4 24
$12.8M
Q3 24
$30.7M
Q2 24
$23.9M
Q1 24
$519.7M
$23.8M
Total Debt
BBIO
BBIO
HTLD
HTLD
Q4 25
$2.0B
$154.1M
Q3 25
$2.0B
Q2 25
Q1 25
Q4 24
$187.9M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BBIO
BBIO
HTLD
HTLD
Q4 25
$-2.1B
$755.3M
Q3 25
$-1.9B
$775.6M
Q2 25
$-1.8B
$786.7M
Q1 25
$-1.6B
$807.7M
Q4 24
$822.6M
Q3 24
$825.7M
Q2 24
$836.8M
Q1 24
$-1.0B
$848.8M
Total Assets
BBIO
BBIO
HTLD
HTLD
Q4 25
$936.0M
$1.2B
Q3 25
$998.3M
$1.3B
Q2 25
$1.1B
$1.3B
Q1 25
$881.6M
$1.3B
Q4 24
$1.3B
Q3 24
$1.4B
Q2 24
$1.4B
Q1 24
$849.3M
$1.5B
Debt / Equity
BBIO
BBIO
HTLD
HTLD
Q4 25
0.20×
Q3 25
Q2 25
Q1 25
Q4 24
0.23×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
HTLD
HTLD
Operating Cash FlowLast quarter
$-56.4M
$14.9M
Free Cash FlowOCF − Capex
$-56.5M
$-44.2M
FCF MarginFCF / Revenue
-36.6%
-24.6%
Capex IntensityCapex / Revenue
0.0%
33.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-66.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
HTLD
HTLD
Q4 25
$-56.4M
$14.9M
Q3 25
$-109.6M
$27.5M
Q2 25
$-80.7M
$21.0M
Q1 25
$-199.2M
$25.8M
Q4 24
$37.8M
Q3 24
$35.6M
Q2 24
$40.0M
Q1 24
$-219.5M
$31.0M
Free Cash Flow
BBIO
BBIO
HTLD
HTLD
Q4 25
$-56.5M
$-44.2M
Q3 25
$-110.0M
$-12.2M
Q2 25
$-81.3M
$-12.8M
Q1 25
$2.3M
Q4 24
$-45.5M
Q3 24
$24.6M
Q2 24
$29.4M
Q1 24
$-220.2M
$26.3M
FCF Margin
BBIO
BBIO
HTLD
HTLD
Q4 25
-36.6%
-24.6%
Q3 25
-91.2%
-6.2%
Q2 25
-73.5%
-6.1%
Q1 25
1.0%
Q4 24
-18.8%
Q3 24
9.5%
Q2 24
10.7%
Q1 24
-104.3%
9.7%
Capex Intensity
BBIO
BBIO
HTLD
HTLD
Q4 25
0.0%
33.0%
Q3 25
0.4%
20.2%
Q2 25
0.5%
16.1%
Q1 25
0.0%
10.7%
Q4 24
34.3%
Q3 24
4.2%
Q2 24
3.8%
Q1 24
0.3%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons